# A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

> **NCT05582993** · PHASE3 · RECRUITING · sponsor: **Takeda** · enrollment: 24 (estimated)

## Conditions studied

- Von Willebrand Disease (VWD)

## Interventions

- **BIOLOGICAL:** Vonicog Alfa
- **BIOLOGICAL:** ADVATE

## Key facts

- **NCT ID:** NCT05582993
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-06
- **Primary completion:** 2030-04-11
- **Final completion:** 2030-04-11
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05582993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05582993, "A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05582993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*